Tag: biotech
Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3
Altimmune (ALT) is rated Sell as the stock already prices in Phase 3 success while the business remains pre-revenue. Despite $326.3 million in cash and a strong current ratio, negative free cash flow and heavy development spending keep the risk profile elevated.
Schrödinger Stock Analysis: Buy or Sell? Valuation & Cash Burn
Schrödinger (SDGR) is rated Sell because its platform quality has not yet translated into durable cash generation. The valuation still assumes stronger growth, while operating cash flow remains deeply negative and free cash flow is not consistently positive.